Fragment Autoantigens Stimulated T‐Cell‐Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine
Abstract Tumor cells often down‐regulate antigen presentation and mount an immunosuppressive microenvironment, hindering successful cancer immunotherapy and vaccine development. Additionally, due to genomic instability, tumor cells are usually heterogeneous and constantly evolving. Therefore, vaccin...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202502937 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Tumor cells often down‐regulate antigen presentation and mount an immunosuppressive microenvironment, hindering successful cancer immunotherapy and vaccine development. Additionally, due to genomic instability, tumor cells are usually heterogeneous and constantly evolving. Therefore, vaccines need broad antigen coverage and rapid preparation. Here, a personalized whole tumor cell vaccine (TCV), termed fragment autoantigens stimulated T‐cell‐immunotherapy (FAST) is developed. In 7 h, tumor cells are treated with irradiation and cryoablation. Personalized fragmented antigens (FAs) from these treated cells are used as TCVs. In breast, colon, and melanoma mouse models, FAST achieved significant tumor regression, less metastasis, and longer survival. Notably, FAST outperforms other advanced TCVs, especially in curbing metastasis. Mechanistically, FAs activate efficient, broad‐spectrum antigen presentation due to upregulation of immunogenic cell death, MHC‐I, and damage‐associated molecular patterns. Concurrently, FAST also enhances anti‐tumor immunity by reshaping immune microenvironments. Analysis of clinical data shows FAST‐associated proteins have prognostic and therapeutic value in patients with liver, stomach, rectal cancers, and melanoma. These results suggest FAST has high anti‐tumor efficacy and potential as a personalized TCV platform. The relevant clinical trial NCT06756295 is under initiation with approval of ethics. |
|---|---|
| ISSN: | 2198-3844 |